M Rimini, M Kudo, T Tada, S Shigeo, W Kang, G Suda, A Jefremow, V Burgio, M Iavarone, R Tortora, F Marra, S Lonardi, E Tamburini, F Piscaglia, G Masi, G Cabibbo, F G Foschi, M Silletta, T Kumada, H Iwamoto, T Aoki, M J Goh, N Sakamoto, J Siebler, A Hiraoka, T Niizeki, K Ueshima, T Sho, M Atsukawa, M Hirooka, K Tsuji, T Ishikawa, K Takaguchi, K Kariyama, E Itobayashi, K Tajiri, N Shimada, H Shibata, H Ochi, S Yasuda, H Toyoda, S Fukunishi, H Ohama, K Kawata, J Tani, S Nakamura, K Nouso, A Tsutsui, T Nagano, T Takaaki, N Itokawa, T Okubo, T Arai, M Imai, K Joko, Y Koizumi, Y Hiasa, A Cucchetti, F Ratti, L Aldrighetti, S Cascinu, A Casadei-Gardini
BACKGROUND: Hepatocellular carcinoma (HCC) treatment remains a big challenge in the field of oncology. The liver disease (viral or not viral) underlying HCC turned out to be crucial in determining the biologic behavior of the tumor, including its response to treatment. The aim of this analysis was to investigate the role of the etiology of the underlying liver disease in survival outcomes. PATIENTS AND METHODS: We conducted a multicenter retrospective study on a large cohort of patients treated with lenvatinib as first-line therapy for advanced HCC from both Eastern and Western institutions...
December 2021: ESMO Open